VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Dengue virus DNA vaccine 1040D2MEL encoding dengue-2 prM-E-LAMP chimeric protein
Vaccine Information
  • Vaccine Name: Dengue virus DNA vaccine 1040D2MEL encoding dengue-2 prM-E-LAMP chimeric protein
  • Target Pathogen: Dengue Virus
  • Target Disease: Dengue Fever
  • Vaccine Ontology ID: VO_0004473
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • Antigen: E, prM, and LAMP from dengue virus 2 New Guinea C (Raviprakash et al., 2001)
  • prM from Dengue virus 2 gene engineering:
    • Type: DNA vaccine construction
    • Description:
    • Detailed Gene Information: Click Here.
  • E protein from Dengue Virus 2 gene engineering:
    • Type: DNA vaccine construction
    • Description:
    • Detailed Gene Information: Click Here.
  • DNA vaccine plasmid:
    • DNA vaccine plasmid name:
    • DNA vaccine plasmid VO ID: VO_0005034
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Mouse Response

  • Vaccine Immune Response Type: VO_0000286
  • Efficacy: When injected into mice, D2MEL elicited an enhanced antibody response compared to D2ME, which was further augmented by coimmunization with a plasmid expressing mouse granulocyte-monocyte colony stimulating factor (GM-CSF). Neutralizing antibodies are thought to be of paramount importance for protection against dengue disease (Raviprakash et al., 2001).
References
Raviprakash et al., 2001: Raviprakash K, Marques E, Ewing D, Lu Y, Phillips I, Porter KR, Kochel TJ, August TJ, Hayes CG, Murphy GS. Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF. Virology. 2001; 290(1); 74-82. [PubMed: 11883007].